Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes

Published:2012-03-14 Issue:8 Volume:14 Page:709-716
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:

Author:

Katz L. B.,Gambale J. J.,Rothenberg P. L.,Vanapalli S. R.,Vaccaro N.,Xi L.,Sarich T. C.,Stein P. P.

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1463-1326.2012.01587.x/fullpdf

Reference26 articles.

1. A gut feeling for obesity: 7TM sensors on enteroendocrine cells.;Engelstoft;Cell Metab,2008

2. Receptors for acylethanol amides-GPR55 and GPR119.;Godlewski;Prostaglandins Other Lipid Mediat,2009

3. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes.;Ahren;Nature Rev,2009

4. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.;Overton;Br J Pharmacol,2008

5. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.;Chu;Endocrinology,2007

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical pharmacokinetics, pharmacodynamics, and toxicity of novel small-molecule GPR119 agonists to treat type-2 diabetes and obesity;Biomedicine & Pharmacotherapy;2024-08

2. GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates;Expert Opinion on Investigational Drugs;2024-02-23

3. Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease;Current Pharmaceutical Design;2023-09-06

4. Antidiabetic agents: Do they hit the right targets?;Frigid Zone Medicine;2022-12-01

5. Targeting the Enteroendocrine System for Treatment of Obesity;From Obesity to Diabetes;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3